Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals

Key Inclusion Criteria: * A clinical diagnosis of acute ischemic stroke in the MCA territory (PCA and/or ACA territory involvement in addition to primary MCA territory stroke is acceptable). * Prior to stroke, no disability, or no significant disability despite symptoms (able to carry out all usual duties and activities). * A baseline DWI lesion between 82 and 300 cm3 on MRI. * Patients treated with IV rtPA should meet established criteria for IV rtPA administration in the 0-3 and 3-4.5 hr time periods at the time of rtPA administration (if rtPA is administered in the 3-4.5 hr time window, the NIHSS must be ≤ 25 at the time of rtPA administration). * The time to the start of infusion of Study Drug must be ≤ 10 hours after time of symptom onset, if known, or the time last seen well \[termed "time last known at neurologic baseline" (TLK@B)\]. * Provision of written informed consent by a legally authorized representative according to institutional guidelines and national regulations. Key Exclusion Criteria: * Commitment to decompressive craniectomy (DC) prior to enrollment, or following enrollment and prior to start of Study Drug. * Treatment with intra-arterial (IA) rtPA or by mechanical means for clot disruption. * Patients unable to tolerate MRI scanning, e.g. those with pacemakers or automatic defibrillators. * Evidence (clinical or imaging) of concurrent infarction in the contralateral hemisphere deemed by the investigator to be sufficiently serious so as to affect functional outcome. * Clinical signs of herniation, e.g. one or two dilated, fixed pupils; unconsciousness (i.e., ≥ 2 on item 1a on the NIHSS); and/or loss of other brain stem reflexes attributable to edema or herniation according to the investigator's judgment. * Hemorrhage (other than small petechial hemorrhages) on CT/MRI, or CT/MRI evidence of anteroseptal/pineal shift greater ≥2 mm prior to enrollment that is due to cerebral edema. * Severe renal disorder from the patient's history (e.g. dialysis) or eGFR of \< 30 mL/min/1.73 m2. * Severe liver disease or ALT \>3 times normal, or bilirubin \>2 times normal. * Blood glucose \<55 mg/dL at enrollment or immediately prior to administration of Study Drug, or a clinically significant history of hypoglycemia. * Acute ST elevation myocardial infarction, and/or acute decompensated HF, and/or QTc\>520 ms, and/or known history of cardiac arrest (PEA, VT, VF, asystole), and/or admission for an ACS, MI, or coronary intervention (PCI or coronary artery surgery) within the past 3 months. * Known sulfonylurea treatment within 7 days. Sulfonylureas include glyburide /glibenclamide (Diabeta, Glynase); glyburide plus metformin (Glucovance); glimepiride (Amaryl); repaglinide (Prandin); netaglinide (Starlix); glipizide (Glucotrol, GlibeneseR, MinodiabR); gliclazide (DiamicronR); tolbutamide (Orinase, Tolinase); glibornuride (Glutril). * Known allergy to sulfa or specific allergy to sulfonylurea drugs. * Known G6PD enzyme deficiency. * Pregnant women. Women must be either post-menopausal (as confirmed by the LAR), permanently sterilized or, if ≤ 50 years old must have a negative test for pregnancy obtained before enrollment. * Breast-feeding women who do not agree (or their LAR does not agree) to stop breast- feeding during Study Drug infusion and for 7 days following the end of Study Drug infusion. * Patients already enrolled in a non-observation-only stroke study, or with life-expectancy \<3 months not related to current stroke, or those unlikely to be compliant with follow up. * Patients currently receiving an investigational drug. * Patients in whom a peripheral IV line cannot be placed. * Mentally incompetent (prior to qualifying stroke) patients and wards of the state. * Patients who, in the opinion of the investigator, are not suitable for the study (reason to be documented). NOTE: Other protocol defined inclusion/exclusion criteria may apply